Rituximab shows great promise in refractory childhood-onset lupus erythematosus panniculitis

  • JAMA Dermatol

  • Emily Willingham, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Rituximab shows promise in a small case series of children with refractory childhood-onset lupus erythematosus panniculitis (LEP).

Why this matters

  • LEP is a disfiguring condition, but large studies of specific therapies would be difficult to conduct because of its rarity.

Key results

  • 3 patients were male (2 were brothers) and 1 was female, aged 18, 22, 7, and 8 years, respectively.
  • All 4 had a “rapid and sustained” response to the rituximab therapy.
  • The only adverse event was a minor infusion reaction in 1 patient.

Study design

  • Retrospective observational case series, single tertiary-care clinic.
  • Outcomes were a decrease in number and size of red, tender nodules (palpated or visually); reduction in facial atrophy; tolerability.
  • Funding: None disclosed.

Limitations

  • A small case series at a single institution.